Ligand Pharmaceuticals Incorporated
Statements
Income Statement
Ligand Pharmaceuticals Incorporated (LGND) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 64 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22 | 38 | 29 | 28 | 33 | 50 | 56 | 90 | 46 | 60 | 43 | 25 | 25 | 27 | 33 | 41 | 42 | 70 | 55 | 85 | 65 | 72 | 37 | 50 | 59 | 27 | 44 | 26 | 33 | 28 | 31 | 42 | 52 | 43 | 45 | 48 | 115 | 60 | 52 | 64 | 291 | |
| 1.0 | 2.9 | 0.3 | 0.9 | 2.4 | 1.7 | 0.8 | 1.1 | 1.5 | 3.0 | 3.9 | 2.4 | 3.1 | 1.9 | 4.7 | 7.6 | 6.4 | 12 | 8.2 | 31 | 11 | 12 | 4.7 | 12 | 14 | 22 | 3.7 | 1.7 | 3.5 | 1.7 | 11 | -15 | 12 | 2.8 | 4.8 | 2.9 | 25 | -26 | 2.1 | 3.2 | 4.1 | |
| 21 | 35 | 29 | 27 | 31 | 49 | 55 | 89 | 44 | 57 | 40 | 23 | 22 | 25 | 28 | 34 | 35 | 58 | 47 | 54 | 53 | 60 | 32 | 38 | 45 | 5.4 | 40 | 25 | 29 | 26 | 20 | 57 | 39 | 40 | 40 | 45 | 91 | 86 | 50 | 60 | 286 | |
| 6.3 | 6.4 | 8.7 | 4.8 | 4.8 | 8.6 | 7.4 | 6.1 | 5.5 | 8.8 | 11 | 12 | 14 | 19 | 12 | 13 | 13 | 22 | 18 | 16 | 17 | 18 | 9.2 | 8.5 | 9.2 | 25 | 6.7 | 6.9 | 5.5 | 5.5 | 6.0 | 5.4 | 5.7 | 4.4 | 50 | 6.6 | 21 | 3.5 | 2.1 | 15 | 41 | |
| 6.3 | 6.6 | 7.3 | 6.5 | 7.0 | 7.7 | 7.6 | 9.3 | 9.6 | 11 | 11 | 11 | 9.5 | 10 | 9.3 | 10 | 15 | 30 | 13 | 15 | 13 | 18 | 12 | 12 | 15 | 20 | 11 | 11 | 15 | 16 | 11 | 18 | 24 | 26 | 19 | 20 | 28 | 25 | 21 | 29 | 103 | |
| 15 | 16 | 19 | 14 | 14 | 20 | 18 | 19 | 21 | 23 | 26 | 27 | 27 | 35 | 25 | 27 | 32 | 47 | 42 | 8.3 | 38 | 48 | 30 | 29 | 33 | -6.7 | 26 | 27 | 26 | 30 | 17 | 76 | 36 | 50 | 77 | 36 | 36 | 66 | 32 | 52 | 185 | |
| 5.5 | 19 | 10 | 13 | 16 | 28 | 37 | 70 | 23 | 33 | 827 | -4.1 | -5.2 | -10 | 3.8 | 7.1 | 3.7 | 11 | 4.7 | 46 | 16 | 13 | 2.1 | 8.7 | 12 | 12 | 14 | -2.0 | 3.1 | -3.4 | 3.0 | -19 | 3.1 | -9.6 | -36 | 8.4 | 55 | 20 | 17 | 8.6 | 101 | |
| 3.1 | 3.0 | 2.9 | 3.3 | 3.4 | 2.8 | 3.5 | 13 | 11 | 20 | 8.9 | 9.0 | 9.0 | 8.8 | 8.5 | 6.2 | 6.3 | 6.4 | 5.8 | 4.9 | 4.4 | 4.5 | 0.8 | 0.4 | 0.3 | 0.2 | 0.2 | 0.3 | 0.0 | 0.1 | 0.1 | 1.3 | 0.7 | 0.9 | 0.9 | 1.2 | 0.9 | 1.8 | 1.7 | 1.7 | 6.2 | |
| 0.8 | 7.2 | 6.2 | 8.3 | 12 | 31 | 55 | 96 | 79 | -57 | 843 | -18 | -20 | -8.2 | -30 | 28 | -12 | 3.4 | 5.8 | 33 | 15 | -7.0 | -9.1 | 8.7 | 12 | 56 | 56 | 3.2 | -12 | 17 | 113 | -65 | -6.3 | -39 | -50 | 11 | 141 | 57 | -24 | 64 | 238 | |
| 0.2 | 10 | 1.1 | 2.2 | 3.6 | 38 | 10 | 22 | 12 | -14 | 176 | -3.6 | -4.6 | -0.8 | -6.3 | 6.0 | -4.9 | -2.4 | -12 | 2.6 | 1.5 | -1.6 | 3.8 | -3.9 | 2.7 | 45 | 12 | 0.9 | -1.9 | -1.1 | 27 | -13 | 0.8 | -8.1 | -7.7 | 6.4 | 24 | 12 | -11 | 16 | 41 | |
| 0.6 | -3.1 | 5.1 | 6.1 | 8.4 | -7.0 | 45 | 73 | 67 | -42 | 666 | -14 | -15 | -7.4 | -24 | 22 | -6.7 | 5.8 | 18 | 31 | 14 | -5.4 | -15 | -0.9 | 0.4 | -17 | 42 | 2.3 | -10 | 18 | 86 | -52 | -7.2 | -31 | -42 | 4.8 | 117 | 45 | -13 | 49 | 197 | |
| 8.4 | 22 | 13 | 16 | 18 | 32 | 61 | 112 | 96 | -33 | 20 | -2.1 | -2.3 | 23 | -15 | 39 | -0.8 | 23 | 25 | 24 | 25 | 10 | 5.3 | 22 | 26 | 67 | 65 | 13 | -3.5 | 26 | 122 | -55 | 3.4 | -30 | -41 | 21 | 149 | 66 | -14 | 72 | 274 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.